Companies:
49,725
Total Market Cap:
135095884375175.46
Global Rank
#28069
Country Rank
#1552
Market Cap
60.66 M
Price
1.16
Change (%)
29.96%
Volume
4.15 M
Bridge Biotherapeutics's latest marketcap:
60.66 M
As of 06/24/2025, Bridge Biotherapeutics's market capitalization has reached $60.66 M. According to our data, Bridge Biotherapeutics is the 28069th most valuable company globally by market capitalization. Market capitalization, commonly referred to as market cap, represents the total market value of all outstanding shares of a publicly traded company and is often used as a measure of company value.
| Market Cap | 60.66 M |
| Revenue (ttm) | 8,159.99 |
| Net Income (ttm) | -14,066,145.5 |
| Shares Out | 52.19 M |
| EPS (ttm) | -0.31 |
| Forward PE | 0.00 |
| Ex-Dividend Date | n/a |
| Earnings Date | 08/10/2025 |
Market Cap Chart
Data Updated: 06/24/2025
Bridge Biotherapeutics's yearly market capitalization.
Bridge Biotherapeutics has seen its market value drop from ₩317.28 B to ₩60.66 M since 2019, representing a total decrease of 99.98% and an annual compound decline rate (CAGR) of 79.00%.
| Date | Market Cap | Change (%) | Global Rank |
|---|---|---|---|
| 06/24/2025 | ₩60.66 M | -73.96% | 28069 |
| 12/30/2024 | ₩189.04 B | 158.57% | 21787 |
| 12/28/2023 | ₩73.11 B | -68.32% | 26995 |
| 12/29/2022 | ₩230.8 B | -17.53% | 18565 |
| 12/30/2021 | ₩279.85 B | 0.27% | 17899 |
| 12/30/2020 | ₩279.09 B | -12.04% | 15397 |
| 12/30/2019 | ₩317.28 B | 13239 |
Company Profile
About Bridge Biotherapeutics, Inc.
Bridge Biotherapeutics, Inc. is a clinical-stage biotechnology company focused on developing innovative therapeutics for ulcerative colitis, fibrotic diseases, and cancers. Headquartered in Seongnam, Korea, the company was founded in 2015.
Pipeline Highlights
- BBT-401: A Pellino-1 inhibitor currently in Phase I clinical trials for ulcerative colitis.
- BBT-877: An autotaxin inhibitor in Phase I trials targeting fibrotic diseases, including idiopathic pulmonary fibrosis.
Strategic Collaborations
Bridge Biotherapeutics has established key partnerships to advance its research:
- Atomwise: Leveraging AI-driven drug discovery for small molecule programs.
- University of Colorado School of Medicine: Investigating BBT-877's potential in immuno-oncology.
- Emory University School of Medicine: Exploring combination therapies for KRAS/P53 mutant NSCLC patients resistant to anti-PD-1 treatments.
Frequently Asked Questions
-
What is Bridge Biotherapeutics's (KOSDAQ-288330) current market cap?As of 06/24/2025, Bridge Biotherapeutics (including the parent company, if applicable) has an estimated market capitalization of $60.66 M USD. This figure represents the total market value of its outstanding shares, including different share classes. Please note that market capitalization fluctuates based on market conditions, and the actual valuation may differ from the latest estimate.
-
Where does Bridge Biotherapeutics (KOSDAQ-288330) rank globally by market cap?Bridge Biotherapeutics global market capitalization ranking is approximately 28069 as of 06/24/2025. This ranking is relative to all publicly traded companies worldwide and can fluctuate based on market dynamics and the performance of other companies. You can refer to our Global companies market cap ranking for the most up-to-date ranking.